Trial of Anti-Malarial Drug Enrolling Subjects

"The increasing problem of drug resistance demands that we continue to find new and effective treatment options for malaria infection," said NIAID Director Dr. Anthony S. Fauci, M.D.

Enrollment has begun in a Phase 1 clinical trial to test the safety of a new investigational drug designed to treat malaria, as well as its effect on the human body, NIH announced Sept. 10, saying this first-in-human study is sponsored by the National Institute of Allergy and Infectious Diseases and is being conducted at the Duke University School of Medicine in Durham, N.C.

In 2016, an estimated 216 million new malaria cases and 445,000 deaths occurred, primarily among children living in sub-Saharan Africa, according to the World Health Organization. While several approved treatments for the mosquito-borne disease exist, increasing drug resistance among the malaria-causing parasites is diminishing their effectiveness, according to NIH.

"The increasing problem of drug resistance demands that we continue to find new and effective treatment options for malaria infection," said NIAID Director Dr. Anthony S. Fauci, M.D.

The study is led by principal investigator Dr. Michael Cohen-Wolkowiez, M.D., Ph.D., professor of pediatrics at the Duke Clinical Research Institute. It is testing an investigational drug called DM1157 that was invented at Portland State University and developed by DesignMedix, both based in Portland, Ore. The novel treatment is a modified form of chloroquine, an established antimalarial drug that kills malaria parasites once they have infected human red blood cells. Many strains of Plasmodium falciparum parasites, which cause the deadliest form of malaria, are now resistant to chloroquine, and the parasites can expel the drug before it can affect them. Like chloroquine, DM1157 interferes with the parasite's metabolism, but it also inhibits the parasite's ability to expel the drug. Results of earlier tests in animals suggest that DM1157 could have the same safety and efficacy as chloroquine.

The will enroll up to 104 healthy volunteers between the ages of 18 and 45 years old. The study is expected to be completed by June 2019.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch in 2019

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January 2019

    Featuring:

    • PREVENTING ERRORS
      Production vs. Safety 
    • EMERGENCY SHOWERS & EYEWASH
      Meeting the Requirements for Emergency Equipment
    • CONSTRUCTION SAFETY
      The State of Contractor Safety
    • FOOT PROTECTION
      The Three Keys to Effective Chemical Management
    View This Issue